文献速递膀胱癌与上尿路尿路上皮癌

UGN-102用于复发性低级别中危非肌层浸润性膀胱癌的初次化学消融:ENVISION单臂开放标签3期试验

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
PubMed 文献 · J Urol · 2024-10-24

ENVISION是一项正在进行的跨国单臂3期研究,评估UGN-102(丝裂霉素)膀胱内灌注对复发性低级别中危非肌层浸润性膀胱癌的初次化学消融疗效与安全性。240例入组患者中191例(80%;95%CI 73.9-84.5)在3个月时达到完全缓解,达到完全缓解者12个月后维持无病的概率为82%(95%CI 75.9-87.1)。作者认为其获益-风险特征良好,支持UGN-102作为该人群经尿道膀胱肿瘤电切术的非手术替代方案。

要点

  • 240例复发性低级别中危非肌层浸润性膀胱癌患者接受UGN-102膀胱灌注,191例(80%)3个月达完全缓解。
  • 达到完全缓解者12个月后维持无病的概率为82%(95%CI 75.9-87.1)。
  • 严重不良事件29/240(12.1%),其中2例与治疗相关(尿潴留/尿道狭窄),均缓解。

核心结论

  • UGN-102初次化学消融治疗复发性低级别中危非肌层浸润性膀胱癌的完全缓解率为80%,达到完全缓解者1年后维持无病的可能性为82%。
  • 作者认为获益-风险特征良好,支持UGN-102作为该人群经尿道膀胱肿瘤电切术的非手术替代方案。

研究设计与样本

  • ENVISION为正在进行的跨国、单臂、3期研究,纳入经活检证实为复发性、未经治疗的低级别中危非肌层浸润性膀胱癌患者。
  • 患者接受6次每周1次的UGN-102(丝裂霉素)膀胱内灌注(门诊环境),3个月时评估。
  • 达到完全缓解(膀胱镜检查、细胞学及针对性活检均阴性)者定期监测直至复发、进展或死亡;无病者随访至5年。

主要发现

  • 240例入组患者中228例(95%)完成全部6次计划剂量。
  • 191例(80%;95%CI 73.9-84.5)在3个月时达到完全缓解,12个月后应答概率为82%(95%CI 75.9-87.1)。
  • 在中位13.9个月随访期内,中位缓解持续时间不可估计。
  • 最常见不良事件(≥5.0%患者)为排尿困难、血尿、尿路感染、尿频、疲乏和尿潴留,总体为轻/中度且已缓解/正在缓解。
  • 严重不良事件29/240(12.1%),其中2例与治疗相关(尿潴留/尿道狭窄),均缓解。

临床怎么用

  • 作者认为UGN-102可作为该患者人群经尿道膀胱肿瘤电切术的非手术替代方案。

局限性

  • 本研究局限性包括诊断性活检后缺乏肿瘤大小评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluate the efficacy and safety of UGN-102 chemoablation for the primary treatment of patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with a biopsy-proven recurrence of untreated low-grade intermediate-risk nonmuscle-invasive bladder cancer. Patients received 6 weekly intravesical instillations of UGN-102 (mitomycin; outpatient setting) and were evaluated at 3 months. Patients achieving complete response (CR; negative cystoscopic examination, cytology, and for-cause biopsy) were surveilled regularly until recurrence, progression, or death. Patients who remain disease-free will be followed up to 5 years, and further results will be reported in the future. RESULTS: Of 240 patients enrolled, 228 (95%) received all 6 planned doses; 191 (80%; 95% CI, 73.9-84.5) achieved CR at 3 months, with an 82% (95% CI, 75.9-87.1) probability of response 12 months later. Median duration of response was not estimable over a median 13.9-month follow-up period. The most common adverse events (≥5.0% of patients) were dysuria, hematuria, UTI, pollakiuria, fatigue, and urinary retention; generally mild/moderate and resolved/resolving. Serious adverse events were observed in 29/240 (12.1%); 2 were treatment related (urinary retention/urethral stenosis), and both resolved. CONCLUSIONS: Primary chemoablation with UGN-102 in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer resulted in an 80% CR rate. Patients achieving a CR had an 82% likelihood of remaining disease-free 1 year later. The benefit-risk profile was favorable, supporting UGN-102 as a nonsurgical alternative for transurethral resection of bladder tumors in this patient population. Limitations of this study included lack of tumor sizing after the diagnostic biopsy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05243550.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Prasad SM, Shishkov D, Mihaylov NV, et al. Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). J Urol. 2024. PMID: 39446087. doi:10.1097/JU.0000000000004296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。